Albemarle Corporation (ALB)
NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-07
$129.03-3.57%
Close 2026-07-07 · 1-day change
Reading ALB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ALB free→NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-07
Reading ALB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ALB free→QuarterlyIQ Insights · ALB
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. Current price $129.03. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $129 the market pays 55× p/e — above the 23× p/e peer median but in line with its own 57× history. That premium reflects a durable franchise our peer-anchored $152 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts target $189–$264. Note: our $152 fair value sits below the entire analyst range ($189–$264). Not investment advice.
$189.00 – $264.00 (median $245.00) · 11 analysts · as of 2026-05-26
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $245.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $27.17 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $22.50 | — | — | Hist. CAGR | high |
| graham number | 12M | $66.99 | — | — | TTM | high |
| Mgmt guidance | 12M | $93.10 | 22.7 | 4.10 | Mgmt | high |
| Peer EV/EBITDA | 12M | $87.42 | 15.2 | 6.21 | TTM | high |
| Peer P/FCF | 12M | $109.63 | 22.5 | 4.87 | TTM | high |
| Peer P/E | 12M | $53.13 | 22.7 | 2.34 | TTM | high |
| Peer P/S | 12M | $66.65 | 1.4 | 46.33 | TTM | high |
| residual income | 12M | $61.14 | — | — | TTM | high |
| Own P/E history | 12M | $133.60 | 57.1 | 2.34 | TTM | high |
| triangulated | 12M | $56.96 | 22.7 | 2.51 | Triangulated | high |
| Peer P/FCF | 3Y | $64.77 | 22.5 | 2.88 | Hist. CAGR(prov.) | low |
| Peer P/E | 3Y | $352.25 | 22.7 | 15.51 | Hist. CAGR(prov.) | low |
| Peer P/S | 3Y | $97.58 | 1.4 | 67.83 | guidance | low |
| Own P/E history | 3Y | $885.69 | 57.1 | 15.51 | Hist. CAGR(prov.) | low |
| Peer P/FCF | 5Y | $45.60 | 22.5 | 2.02 | Hist. CAGR(prov.) | low |
| Peer P/E | 5Y | $465.85 | 22.7 | 20.52 | Hist. CAGR(prov.) | low |
| Peer P/S | 5Y | $129.05 | 1.4 | 89.70 | guidance | low |
| Own P/E history | 5Y | $1171.33 | 57.1 | 20.52 | Hist. CAGR(prov.) | low |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.